AP765A - Ziprasidone mesylate dihydrates and its uses as dopamine D2 atagonists. - Google Patents

Ziprasidone mesylate dihydrates and its uses as dopamine D2 atagonists. Download PDF

Info

Publication number
AP765A
AP765A APAP/P/1997/000976A AP9700976A AP765A AP 765 A AP765 A AP 765A AP 9700976 A AP9700976 A AP 9700976A AP 765 A AP765 A AP 765A
Authority
AP
ARIPO
Prior art keywords
ziprasidone mesylate
ziprasidone
crystals
mesylate
dihydrate
Prior art date
Application number
APAP/P/1997/000976A
Other languages
English (en)
Other versions
AP9700976A0 (en
Inventor
Frank Robert Busch
Carol Anne Rose
Russell James Shine
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AP9700976A0 publication Critical patent/AP9700976A0/xx
Application granted granted Critical
Publication of AP765A publication Critical patent/AP765A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Saccharide Compounds (AREA)
APAP/P/1997/000976A 1996-05-07 1997-04-30 Ziprasidone mesylate dihydrates and its uses as dopamine D2 atagonists. AP765A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1675796P 1996-05-07 1996-05-07

Publications (2)

Publication Number Publication Date
AP9700976A0 AP9700976A0 (en) 1997-07-31
AP765A true AP765A (en) 1999-09-17

Family

ID=21778804

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1997/000976A AP765A (en) 1996-05-07 1997-04-30 Ziprasidone mesylate dihydrates and its uses as dopamine D2 atagonists.

Country Status (41)

Country Link
US (1) US6245765B1 (ko)
EP (1) EP0918772B1 (ko)
JP (1) JP3494659B2 (ko)
KR (1) KR100333215B1 (ko)
CN (1) CN1091769C (ko)
AP (1) AP765A (ko)
AR (1) AR007004A1 (ko)
AT (1) ATE278689T1 (ko)
AU (1) AU731267B2 (ko)
BG (1) BG63544B1 (ko)
BR (1) BR9709889A (ko)
CA (1) CA2252898C (ko)
CO (1) CO4940466A1 (ko)
CZ (1) CZ289215B6 (ko)
DE (1) DE69731094T2 (ko)
DK (1) DK0918772T3 (ko)
DZ (1) DZ2222A1 (ko)
EA (1) EA001190B1 (ko)
EG (1) EG24076A (ko)
ES (1) ES2229342T3 (ko)
GT (1) GT199700052A (ko)
HK (1) HK1017892A1 (ko)
HR (1) HRP970236B1 (ko)
ID (1) ID16867A (ko)
IL (1) IL126591A (ko)
IS (1) IS2080B (ko)
MA (1) MA24171A1 (ko)
MY (1) MY119997A (ko)
NO (1) NO312514B1 (ko)
NZ (1) NZ332218A (ko)
OA (1) OA10909A (ko)
PL (1) PL188330B1 (ko)
PT (1) PT918772E (ko)
SI (1) SI0918772T1 (ko)
SK (1) SK282837B6 (ko)
TN (1) TNSN97074A1 (ko)
TR (1) TR199802240T2 (ko)
TW (1) TW491847B (ko)
UA (1) UA46840C2 (ko)
WO (1) WO1997042191A1 (ko)
ZA (1) ZA973876B (ko)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
EE200200670A (et) * 2000-06-02 2004-08-16 Pfizer Products Inc. S-metüüldihüdroziprasidoon psühhiaatriliste ja silmahaiguste raviks
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
UY27668A1 (es) * 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
BRPI0410271A (pt) * 2003-05-16 2006-05-16 Pfizer Prod Inc combinações terapêuticas de antipsicóticos atìpicos com moduladores de gaba, anticonvulsivantes ou benzodiazepinas
EP1546146A1 (en) 2003-06-03 2005-06-29 Teva Pharmaceutical Industries Limited POLYMORPHIC FORMS OF ZIPRASIDONE HCl AND PROCESSES FOR THEIR PREPARATION
CA2543805A1 (en) 2003-10-24 2005-05-06 Gideon Pilarsky Processes for preparation of ziprasidone
JP2007537232A (ja) * 2004-05-11 2007-12-20 ファイザー・プロダクツ・インク 非定型抗精神病薬と５−ｈｔ１ｂ受容体拮抗薬の組合せ
CA2467538C (en) 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
CA2471219A1 (en) 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
US7777037B2 (en) * 2004-10-27 2010-08-17 Dr. Reddy's Laboratories Limited Ziprasidone process
US7910577B2 (en) * 2004-11-16 2011-03-22 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
US20060258679A1 (en) * 2005-02-11 2006-11-16 Alex Mainfeld Process of preparing ziprasidone mesylate
US20070032511A1 (en) * 2005-02-11 2007-02-08 Judith Aronhime Amorphous ziprasidone mesylate
CA2598288A1 (en) * 2005-03-03 2006-09-14 Elan Pharma International Limited Nanoparticulate compositions of heterocyclic amide derivatives
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
CA2500667C (en) 2005-03-11 2013-01-15 Apotex Pharmachem Inc. Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions
EP1858892A1 (en) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd Anhydrous ziprasidone mesylate and a process for its preparation
EP1858891A2 (en) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
ITMI20052216A1 (it) * 2005-11-18 2007-05-19 Dipharma Spa Procedimento per la preparazione di ziprasidone
EP2146577A1 (en) * 2007-05-18 2010-01-27 Scidose, Llc Ziprasidone formulations
EP2321011A1 (en) * 2008-06-25 2011-05-18 Pfizer Inc. Diaryl compounds and uses thereof
CN107625728A (zh) * 2010-10-18 2018-01-26 大日本住友制药株式会社 注射用缓释制剂
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
EP0584903A1 (en) * 1992-08-26 1994-03-02 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
WO1995000510A1 (en) * 1993-06-28 1995-01-05 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
JP3102896B2 (ja) 1996-05-07 2000-10-23 ファイザー インク． ５―（２―（４―（１，２―ベンズイソチアゾール―３―イル）―１―ピペラジニル）エチル）―６―クロロ―１，３―ジヒドロ―２（１ｈ）―インドール―２―オン（＝ジプラシドン）のメシレート三水和物、その調製法およびドーパミンｄ２アンタゴニストとしてのその使用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
EP0584903A1 (en) * 1992-08-26 1994-03-02 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
WO1995000510A1 (en) * 1993-06-28 1995-01-05 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one

Also Published As

Publication number Publication date
BG63544B1 (bg) 2002-04-30
PL188330B1 (pl) 2005-01-31
MA24171A1 (fr) 1997-12-31
HK1017892A1 (en) 1999-12-03
HRP970236A2 (en) 1998-06-30
AP9700976A0 (en) 1997-07-31
CA2252898C (en) 2003-04-08
AR007004A1 (es) 1999-10-13
KR20000010824A (ko) 2000-02-25
ATE278689T1 (de) 2004-10-15
SI0918772T1 (en) 2005-02-28
WO1997042191A1 (en) 1997-11-13
CZ349398A3 (cs) 1999-09-15
OA10909A (en) 2001-10-26
DE69731094T2 (de) 2006-02-23
JP3494659B2 (ja) 2004-02-09
EA001190B1 (ru) 2000-12-25
CN1091769C (zh) 2002-10-02
SK150898A3 (en) 2000-02-14
JPH11509867A (ja) 1999-08-31
HRP970236B1 (en) 2002-12-31
TR199802240T2 (ko) 1999-02-22
NO985194D0 (no) 1998-11-06
ID16867A (id) 1997-11-20
IS4874A (is) 1998-10-20
CA2252898A1 (en) 1997-11-13
EP0918772B1 (en) 2004-10-06
UA46840C2 (uk) 2002-06-17
ZA973876B (en) 1998-11-06
BR9709889A (pt) 1999-08-10
DK0918772T3 (da) 2005-01-10
BG102892A (en) 1999-09-30
DE69731094D1 (de) 2004-11-11
EG24076A (en) 2008-05-11
US6245765B1 (en) 2001-06-12
DZ2222A1 (fr) 2002-12-03
EP0918772A1 (en) 1999-06-02
AU731267B2 (en) 2001-03-29
GT199700052A (es) 2001-08-29
ES2229342T3 (es) 2005-04-16
AU2174797A (en) 1997-11-26
TNSN97074A1 (fr) 2005-03-15
NO985194L (no) 1998-11-06
CN1216991A (zh) 1999-05-19
IL126591A (en) 2001-11-25
NO312514B1 (no) 2002-05-21
PL329884A1 (en) 1999-04-12
KR100333215B1 (ko) 2002-06-20
CO4940466A1 (es) 2000-07-24
MY119997A (en) 2005-08-30
IS2080B (is) 2006-02-15
EA199800912A1 (ru) 1999-04-29
PT918772E (pt) 2004-12-31
SK282837B6 (sk) 2002-12-03
CZ289215B6 (cs) 2001-12-12
NZ332218A (en) 2005-02-25
TW491847B (en) 2002-06-21
IL126591A0 (en) 1999-08-17

Similar Documents

Publication Publication Date Title
AP765A (en) Ziprasidone mesylate dihydrates and its uses as dopamine D2 atagonists.
AP838A (en) Mesylate trihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-y1)-1-piperaziny1)-ethy1) -6-chloro-1,3-dihydro-2h-indol-2-one.
NZ508304A (en) Mesylate dihydrate salt of 5-(2-(4-(1,2 benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one ( ziprasidone) useful as dopamine D2 antagonist
MXPA98009242A (en) Salt mesylate trihydrate 5 - (- 2- (4- (1,2-benzoisotiazol-3-il) -1-piperazinil) ethyl) -6-chlorine-1,3-dihydro-2h-indol-2-